Bora Pharmaceuticals and Celltrion Asia Pacific, a subsidiary of Celltrion Group, have joined forces to contract manufacture and commercialize a range of oral solid dosage (OSD) drugs across the Asia-Pacific (APAC) region.

The range of oral dosage form products will be manufactured at Bora’s Zhunan site, which is one of the largest U.S. FDA and MHRA-approved pharmaceutical production facilities in Taiwan.

In addition, the manufactured batches will be used to support Celltrion’s regulatory filings for approval in seven countries, and Bora will further support Celltrion to commercialize the products immediately upon approval by utilizing its cutting-edge manufacturing capabilities in complex oral dosage form and total-solution services. 

“We are extremely excited about this new partnership with Celltrion,” said Bobby Sheng, CEO and chairman of Bora. “As a trusted global partner, we look forward to serving our customers with the best technical and quality resources and supporting our partners to expand into various markets around the world.”